Hydroxychloroquine trial suspended by WHO

Amy Baxter | | Health Exec | Management

The World Health Organization has suspended the trial of the controversial drug hydroxychloroquine due to safety concerns, Axios reported. The report comes just a few weeks after President Trump announced he had been taking the drug as a preventative measure against infection of COVID-19.

Hydroxychloroquine has been touted by Trump as a treatment for COVID-19, though evidence that the drug, which is typically used to treat malaria, is effective against COVID-19 has not been proven. The FDA has also issued a warning that the drug should only be administered in hospitals due to the heart risks.

WHO decided to shut down its trial of the drug as a COVID-19 treatment after patients who took it were more likely to die or develop irregular heart rhythm and potentially sudden cardiac death than those who did nothing. Those findings were recently published in The Lancet, which reviewed 96,000 hospitalized COVID-19 patients in six continents between Dec. 20, 2019 and April 14, 2020.

See the full story below:

WHO temporarily suspends trial of hydroxychloroquine over safety concerns

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Asante Medical facing $488M in lawsuits after fentanyl diversion linked to 16 deaths
FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
Ransomware group deploys ticking clock to threaten Georgia hospital
Private equity transactions in healthcare down 15% since 2023, report finds

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”